NTLA Projected Dividend Yield
Intellia Therapeutics Inc ( NASDAQ : NTLA )Intellia Therapeutics is a genome editing company focused on developing therapeutics using CRISPR/Cas9 technology. CRISPR/Cas9, an acronym for Clustered, Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR associated 9 (Cas9), is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid (DNA). To realize the transformative potential of CRISPR/Cas9-based technologies, Co. is building a range of genome editing company, by utilizing its modular platform, to advance in vivo and ex vivo therapies for diseases with high unmet need. 20 YEAR PERFORMANCE RESULTS |
NTLA Dividend History Detail NTLA Dividend News NTLA Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |